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Background
Azidothymidine (AZT), a thymidine analogue, is an excel-
lent substrate for gamma-herpes virus thymidine kinases
(TKs). Our group previously demonstrated that AZT
alone can inhibit NF-B and disrupt EBV latency in pri-
mary low-passage Type I latency EBV+ Burkitt lines. The
addition of hydroxyurea, which increases the intracellular
levels of AZT monophosphate, synergized with AZT in
Type III latency EBV+ immunoblastic lymphoma cell
lines. The use of AZT in targeting gamma-herpes virus
lymphomas is an attractive concept given that this drug is
preferentially phosphorylated by EBV and HHV-8 TKs as
compared to non-thymidine nucleoside analogues. The
drugs methotrexate (MTX) and doxorubicin (DOX) also
induce lytic expression of gamma-herpes viruses. MTX
inhibits thymidylate synthase, thus blocking de novo
synthesis of dTMP and increasing the likelihood of AZT
incorporation into DNA. We have found that the combi-
nation of high-dose AZT with MTX, used alone or with
alternating standard chemotherapy, can result in dramatic
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Table 1
Age
Lymphoma
type Stage PS HIV CD4
Alternating
regimen RT
Sustained Response
(months)
Progression
(months)
Death
(months)
34 DLBCL IVB 3 + 4 - - PD 1.0 1.3
49 BL IVB 2 + 91 EPOCH - CR (50) - -
40 BL IIA 2 - - hCVAD + CR (57) - -
51 DLBCL IVB 2 + 47 EPOCH - CR (65) - -
40 BL IVB 2 + 214 hCVAD - PD 2.0 -
34 PBL IVB 2 + 16 - - PD 1.0 4.5
33 PBL IIA 1 + 166 EPOCH - CR (18) - -
44 PBL IVA 1 + 458 EPOCH - CR (19) - -
52 PBL IIB 1 + 57 EPOCH + CR (20) - -
51 Solid PEL IVB 2 + 113 - - CR (31), 2
nd CR (10) After 1st line: 31.1 -
PS: ECOG performance score; RT: radiotherapy; DLBCL: diffuse large B-cell lymphoma; PEL: primary effusion lymphoma; PBL: plasmablastic lymphoma. EPOCH:
etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; hyper cVAD: dexamethasone and fractionated vincristine, doxorubicin cyclophosphamide; CR:
complete remission; PR: partial remission; PD: progressive disease.
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prognosis gamma-herpes virus-related lymphomas.
Materials and methods
Ten patients with EBV-positive (9 HIV-positive) non-
Hodgkin’s lymphoma (NHL) were treated with first-line
MTX (3.0-4.5 g/m
2 IV on day 1) and AZT 1.5 g IV infu-
sion q12 hours (days 1-4) every 3 weeks or alternated
with other chemotherapy regimens, including EPOCH,
or hyper cVAD between 2004-2009 at the discretion of
the treating physician (Table 1). One patient (solid PEL)
received AZT and MTX initially, and upon relapse 31
months later received DOX 20 mg/m
2 (Day 1) , MTX 5
g/m
2 (Day 2), and AZT 750 mg twice daily with hydro-
xyurea 1 g daily (Days 2-5) under our new clinical trial.
Results
Clinical characteristics, response, and survival data of
patients are summarized in Table 1. All patients were
treated with high-dose AZT and MTX. Three patients
with plasmablastic lymphoma (PBL) and 1 patient with
BL also received alternating EPOCH; 2 BL patients
received alternating hCVAD. Seven patients achieved
CR. Two patients developed neutropenic fever. Median
PFS in this cohort of patients has not been reached.
Median OS was 31 months (95% CI: 0.0-84.8).
Conclusions
The combination of high-dose MTX/AZT is a promis-
ing and tolerable treatment for gamma-herpes virus-
related lymphomas. A Phase II clinical trial with
low-dose doxorubicin, MTX, AZT, and hydroxyurea for
relapse EBV+ NHL is currently recruiting participants.
Interim results and supporting laboratory data for using
this gamma-herpes virus lytic approach will be pre-
sented at the meeting.
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